Share 'Bristol-Myers Squibb Enters into Agreement with Roche to License Anti-Myostatin Compound'
Bristol-Myers Squibb (BMS) today announced that it has entered into an agreement to license BMS-986089, an anti-myostatin adnectin in development for Duchenne muscular dystrophy, to Roche.
Read the announcement from BMS:
Bristol-Myers Squibb Enters into Separate Agreements with Biogen and Roche to License Anti-eTau and Anti-Myostatin Compounds, Respectively
Bristol-Myers Squibb to receive a co…
You can share this blog post in two ways…
Share this link:
Send it with your computer's email program: Email this